Barclays lowered the firm’s price target on Evolent Health (EVH) to $19 from $39 and keeps an Overweight rating on the shares. While the Q3 miss is disappointing, it is not unique for the current risk environment, and the fundamental business model remains intact, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $20 from $42 at RBC Capital
- Evolent Health price target lowered to $36 from $45 at BTIG
- Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz
- Evolent Health falls -42.1%
- Evolent Health price target lowered to $27 from $43 at JMP Securities
Questions or Comments about the article? Write to editor@tipranks.com